Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
260.75
-0.83 (-0.32%)
At close: Jun 26, 2026, 4:00 PM EDT
261.00
+0.25 (0.10%)
After-hours: Jun 26, 2026, 6:16 PM EDT
Ascendis Pharma Employees
Ascendis Pharma had 1,189 employees as of December 31, 2025. The number of employees increased by 172 or 16.91% compared to the previous year.
Employees
1,189
Change (1Y)
172
Growth (1Y)
16.91%
Revenue / Employee
$839,568
Profits / Employee
$480,917
Market Cap
16.20B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1,189 | 172 | 16.91% |
| Dec 31, 2024 | 1,017 | 138 | 15.70% |
| Dec 31, 2023 | 879 | 82 | 10.29% |
| Dec 31, 2022 | 797 | 158 | 24.73% |
| Dec 31, 2021 | 639 | 157 | 32.57% |
| Dec 31, 2020 | 482 | 152 | 46.06% |
| Dec 31, 2019 | 330 | 114 | 52.78% |
| Dec 31, 2018 | 216 | 79 | 57.66% |
| Dec 31, 2017 | 137 | 36 | 35.64% |
| Dec 31, 2016 | 101 | 23 | 29.49% |
| Dec 31, 2015 | 78 | 23 | 41.82% |
| Dec 31, 2014 | 55 | 10 | 22.22% |
| Dec 31, 2013 | 45 | 7 | 18.42% |
| Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 3,088 |
| Jazz Pharmaceuticals | 2,890 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| BridgeBio Pharma | 839 |
ASND News
- 12 hours ago - Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap® - GlobeNewsWire
- 1 day ago - Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026 - GlobeNewsWire
- 13 days ago - Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism - GlobeNewsWire
- 15 days ago - 5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism - GlobeNewsWire
- 18 days ago - Ascendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026 - GlobeNewsWire
- 7 weeks ago - Ascendis Pharma Earnings Call Transcript: Q1 2026 - Transcripts
- 7 weeks ago - Ascendis Pharma Earnings release: Q1 2026 - Filings
- 7 weeks ago - Ascendis Pharma Reports First Quarter 2026 Financial Results - GlobeNewsWire